Balaxi FY26: Margin Improvement Meets Working Capital Pressure

Consolidated revenue for FY26 was 270.17 crore as presented in the FY26 consolidated financial table.

FY26 EBITDA was 11.35 crore versus 33.50 crore in FY25, and FY26 PAT was 1.42 crore versus 25.07 crore in FY25, as per the consolidated performance table.

Gross margin in FY26 was 44.2 percent, compared with 43.4 percent in FY25, according to the consolidated table.

The presentation shows a FY26 geography mix of 52 percent Africa and 48 percent Latin America for pharma product mix.

The company states it has received the manufacturing licence for its first formulation facility at Jadcherla, Hyderabad, and that plant qualification and validation are complete.

The presentation states 964 product registrations across seven countries, and management notes 49 new registrations in Latin America during FY26.